I 

108TH CONGRESS 

1ST SESSION H. R. 290

To expand research regarding inflammatory bowel disease, and for other 

purposes. 

IN THE HOUSE OF REPRESENTATIVES 

JANUARY 8, 2003

Mrs. KELLY introduced the following bill; which was referred to the 

Committee on Energy and Commerce 

A BILL

To expand research regarding inflammatory bowel disease, 

and for other purposes.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Inflammatory Bowel 

5 Disease Act’’. 

6 SEC. 2. FINDINGS. 

7 Congress makes the following findings: 

8 (1) Crohn’s disease and ulcerative colitis are se9 rious inflammatory diseases of the gastrointestinal 

10 tract. Crohn’s disease may occur in any section of 
2

•HR 290 IH 

1 the gastrointestinal tract but is predominately found 

2 in the lower part of the small intestine and the large 

3 intestine. Ulcerative colitis is characterized by in4 flammation and ulceration of the innermost lining of 

5 the colon. Because Crohn’s disease and ulcerative co6 litis behave similarly, they are collectively known as 

7 inflammatory bowel disease. Both diseases present a 

8 variety of symptoms, including severe diarrhea, 

9 crampy abdominal pain, fever, and rectal bleeding. 

10 There is no known cause of inflammatory bowel dis11 ease, or medical cure. 

12 (2) It is estimated that up to 1,000,000 people 

13 in the United States suffer from inflammatory bowel 

14 disease. 

15 (3) In 1990, the total annual medical costs for 

16 Crohn’s disease patients was estimated at 

17 $1,000,000,000 to $1,200,000,000. 

18 (4) In 1990, the total annual medical costs for 

19 ulcerative colitis patients was estimated at 

20 $400,000,000 to $600,000,000. 

21 (5) Inflammatory bowel disease patients are at 

22 high-risk for developing colorectal cancer. 
3

•HR 290 IH 

1 SEC. 3. INFLAMMATORY BOWEL DISEASE RESEARCH EX2 PANSION. 

3 (a) IN GENERAL.—The Director of the National In4 stitute of Diabetes and Digestive and Kidney Diseases 

5 shall expand, intensify, and coordinate the activities of the 

6 Institute with respect to research on inflammatory bowel 

7 disease with particular emphasis on the following areas: 

8 (1) Genetic research on susceptibility for in9 flammatory bowel disease, including the interaction 

10 of genetic and environmental factors in the develop11 ment of the disease. 

12 (2) Animal model research on inflammatory 

13 bowel disease, including genetics in animals. 

14 (3) Clinical inflammatory bowel disease re15 search, including clinical studies and treatment 

16 trials. 

17 (4) Other research initiatives identified by the 

18 scientific document entitled ‘‘Challenges in Inflam19 matory Bowel Disease’’. 

20 (b) AUTHORIZATION OF APPROPRIATIONS.—

21 (1) IN GENERAL.—For the purpose of carrying 

22 out this section, there are authorized to be appro23 priated $75,000,000 in fiscal year 2004, 

24 $100,000,000 in fiscal year 2005, and such sums as 

25 may be necessary for fiscal years 2006 and 2007. 
4

•HR 290 IH 

1 (2) RESERVATION.—Of the funds authorized to 

2 be appropriated under paragraph (1), not more than 

3 20 percent of such funds shall be reserved to fund 

4 the training of qualified health professionals in bio5 medical research focused on inflammatory bowel dis6 ease and related disorders. 

7 SEC. 4. INFLAMMATORY BOWEL DISEASE PREVENTION AND 

8 EPIDEMIOLOGY. 

9 (a) IN GENERAL.—The Director of the Centers for 

10 Disease Control and Prevention shall establish a national 

11 program of prevention and epidemiology to determine the 

12 prevalence of inflammatory bowel disease in the United 

13 States, and conduct public and professional awareness ac14 tivities on inflammatory bowel disease. 

15 (b) AUTHORIZATION OF APPROPRIATIONS.—For the 

16 purpose of carrying out this section, there are authorized 

17 to be appropriated $5,000,000 in fiscal year 2004, and 

18 such sums as may be necessary for fiscal years 2005 

19 through 2007. 

20 SEC. 5. STUDY OF INFLAMMATORY BOWEL DISEASE RE21 LATED SERVICES. 

22 (a) IN GENERAL.—The Institute of Medicine of the 

23 National Academics of Science shall conduct a study on 

24 the coverage standards of medicare, medicaid, and the pri25 vate insurance market for the following therapies: 
5

•HR 290 IH 

1 (1) Parenteral nutrition. 

2 (2) Enteral nutrition formula. 

3 (3) Medically necessary food products. 

4 (4) Ostomy supplies. 

5 (5) Therapies approved by the Food and Drug 

6 Administration for Crohn’s disease and ulcerative 

7 colitis. 

8 (b) CONTENT.—The study shall also take into ac9 count the appropriate outpatient or home health care de10 livery settings. 

11 (c) REPORT.—Not later than 6 months after the date 

12 of enactment of this Act, the Institute of Medicine shall 

13 submit a report to Congress describing the findings of the 

14 study. 

15 (d) AUTHORIZATION OF APPROPRIATIONS.—There 

16 are authorized to be appropriated to carry out this section, 

17 such sums as may be necessary. 

18 SEC. 6. SOCIAL SECURITY DISABILITY FOR INFLAMMATORY 

19 BOWEL DISEASE PATIENTS. 

20 (a) IN GENERAL.—The General Accounting Office 

21 shall conduct a study of the problems patients encounter 

22 when applying for disability insurance benefits under title 

23 II of the Social Security Act. The study will also include 

24 recommendations for improving the application process for 

25 inflammatory bowel disease patients. 
6

•HR 290 IH 

1 (b) REPORT.—Not later than 6 months after the date 

2 of enactment of this Act, the General Accounting Office 

3 shall submit a report to Congress describing the findings 

4 of the study. 

5 (c) AUTHORIZATION OF APPROPRIATIONS.—There 

6 are authorized to be appropriated to carry out this section, 

7 such sums as may be necessary.

Æ